FLT3 and acute myeloid leukemia: In FLT3-ITD–positive AML cell lines, circMYBL2 interacts with the RBP polypyrimidine tract-binding protein 1 to impair AML cell proliferation and overcome acquired resistance to FLT3 tyrosine kinase inhibitor quizartinib.